- ALNY Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-3ASR Filing
Alnylam Pharmaceuticals (ALNY) S-3ASRAutomatic shelf registration
Filed: 21 Dec 12, 12:00am
Exhibit 12
STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF
EARNINGS/DEFICIENCIES TO FIXED CHARGES
(dollars in thousands)
Nine Months ended September 30, 2012 | Fiscal Year Ended December 31, | |||||||||||||||||||||||
2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||||
Earnings (loss): | ||||||||||||||||||||||||
Pre-tax loss from continuing operations before adjustment for loss from equity investee | $ | (40,185 | ) | $ | (54,144 | ) | $ | (35,362 | ) | $ | (42,098 | ) | $ | (16,240 | ) | $ | (79,146 | ) | ||||||
add: Fixed charges (see below) | 896 | 1,207 | 1,207 | 712 | 1,115 | 1,553 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Pre-tax income (loss) from continuing operations before adjustment for income/loss from equity investees plus fixed charges | $ | (39,289 | ) | $ | (52,937 | ) | $ | (34,155 | ) | $ | (41,386 | ) | $ | (15,125 | ) | $ | (77,593 | ) | ||||||
Fixed charges: | ||||||||||||||||||||||||
Interest expense on indebtedness | $ | — | $ | — | $ | — | $ | — | $ | 872 | $ | 1,083 | ||||||||||||
Interest expense on portion of rent expense representative of interest | 896 | 1,207 | 1,207 | 712 | 243 | 470 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total fixed charges | $ | 896 | $ | 1,207 | $ | 1,207 | $ | 712 | $ | 1,115 | $ | 1,553 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of earnings to fixed charges | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Deficiency of earnings available to cover fixed charges | $ | (40,185 | ) | $ | (54,144 | ) | $ | (35,362 | ) | $ | (42,098 | ) | $ | (16,240 | ) | $ | (79,146 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|